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‘Show us the science that use of antibiotics in animal produc-
tion is causing this antibiotic resistance,’ Dave Warner of the
National Pork Council told the Washington Post back in June
2010 [1], responding to a Food and Drug Administration
(FDA) guidance document advising against the sub-therapeu-
tic use of antibiotics in livestock.
Well, here’s some.
The FDA guidance document rapidly became a subject of
political debate, criticized not only by the meat industry, as
cited above, but also by worried scientists for being a hesi-
tant belated step in an important subject that the European
Union has dealt with since 2006. The political nature of the
issue extended to PAMTA, (Preservation of Antibiotics for
Medical Treatment Act), a legislation attempt that has been
at present unfortunate.
Antibiotics have been used in the animal-raising industry
for decades, for three reasons: (i) therapeutically, (ii) preven-
tively (when symptoms of disease emerge in a minority of
animals raised crowded in thousands in a secluded environ-
ment, all animals are treated) and, most controversially, (iii)
as growth promoters: added to the food or water of these
animals, at low, but protractedly administered, doses to
enhance feed efﬁciency and produce larger animals faster and
with less food. It has been estimated that at least 30% of the
total annual antibiotic use (although others raise this per-
centage to > 70%) is for sub-therapeutic purposes [2]. The
ensuing selective pressure leads to the development of anti-
biotic-resistance genes, for example extended-spectrum
beta-lactamase (ESBL), which can then be shed in the envi-
ronment, directly through the food chain, by direct contact,
or through contamination of the water horizon and ﬁelds
from animal waste. A pioneering study by Levy et al. in 1976
[3] demonstrated that tetracycline resistance, and subse-
quently multiple-drug resistance, developed in poultry farms
where tetracycline was used as a growth promoter (but not,
or at least to a lesser extent and belatedly, in farms where
antibiotic additives were not used) and spread to the work-
ers of these farms and their families (but not to unrelated
households of the same area). Since then, the recognition of
the presence of ESBL in poultry and pig farms and in retail
meat has been increasingly recognized in diverse world
regions, including Asia, the USA and Europe [4–6]. Further-
more, it has been demonstrated that ESBLs of zoonotic ori-
gin are similar to those causing clinically signiﬁcant
community-acquired antibiotic-resistant infections. There has
also been increasing concern about the importation of antibi-
otic resistance through retail meat products, as for example
in the UK, where imported retail chicken harbours the
CTX-M-2 gene, which is not indigenous in clinical terms [7],
or in Denmark (a country that was one of the ﬁrst, along
with Sweden, to abolish the sub-therapeutic use of antibiot-
ics in such settings), where meat imported from Germany
was incriminated [8].
This situation goes beyond Escherichia coli. It has been
increasingly recognized in Salmonella spp. [9], Klebsiella pneu-
moniae, methicillin-resistant Staphylococcus aureus [10], and
typically for Enterococcus faecium: the use of the glycopeptide
avoparcin as an additive in the past was directly correlated
to the emergence of glycopeptide-resistant Enterococcus fae-
cium in the community, a situation that reversed upon the
institution of regulations against avoparcin use [11].
However, is there direct evidence of the, at least partial,
zoonotic nature of ESBL and of antibiotic resistance in gen-
eral? Taking into account the substantial ﬁnancial burden that
antibiotic abolition would bring to the industry (ranging
down to individual farms), evidence should spread beyond
epidemiological observations. Enterococcus faecium resistance
patterns offer some evidence, with the emergence of strep-
togramin resistance, which cannot be attributed to extensive
antibiotic use in humans but can be attributed to the use of
virginiamycin as a growth promoter. The study by Lever-
stein-van Hall and colleagues in the present issue of Clinical
Microbiology and Infection offers further evidence. The authors
not only successfully identiﬁed ‘ﬁngerprints’ of animal origin
ESBL in human disease E. coli isolates, but further quantiﬁed
the burden of disease induced by zoonotic resistant species:
which was 2–16 patients in the Netherlands in a period of
3 months. Extrapolating these results to annual cases in a
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wider geographic region underlines the magnitude of the
problem and renders any ﬁnancially related debate useless,
as the Danish experience has already shown: subsequent to
prohibition of the sub-therapeutic use of antibiotics, the
Danish meat industry ﬂourished, instead of exhibiting losses
[2]. Back to politics then, and in need of stern, brave deci-
sions.
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